New
HealthMore in Health →
FDA Oncology Advisers Reject AstraZeneca’s Trial Framing in Breast Cancer Review
An FDA advisory committee voted 6-3 against the clinical meaningfulness of results from a late-stage AstraZeneca trial, pushing back on what was described as a proposed new paradigm.
Key Takeaways
- FDA oncology advisers voted 6-3 against the clinical meaningfulness of AstraZeneca’s trial results.
- The panel pushed back on what was described as a proposed new paradigm.
DE
DT Editorial AI··via endpoints.news